New perspectives on mTOR inhibitors (rapamycin, rapalogs and TORKinibs) in transplantation

A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer

(2016) Thomas Powles et al.   EUROPEAN UROLOGY

Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma

(2016) Edward K. Geissler et al.   TRANSPLANTATION

Rapamycin-mediated mTORC2 inhibition is determined by the relative expression of FK506-binding proteins

(2015) Katherine H. Schreiber et al.   AGING CELL

The Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy inDe NovoRecipients: One-Year Results of a Scandinavian Randomized Trial

(2015) S. Arora et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Rapamycin Prolongs Cardiac Allograft Survival in a Mouse Model by Inducing Myeloid-Derived Suppressor Cells

(2015) T. Nakamura et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses

(2015) H. Tedesco- Silva et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Rapamycin ameliorates the CTLA4-Ig-mediated defect in CD8+ T cell immunity during gammaherpesvirus infection

(2015) D. F. Pinelli et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Synergy between rapamycin and FLT3 ligand enhances plasmacytoid dendritic cell-dependent induction of CD4+CD25+FoxP3+ Treg

(2015) M. Biswas et al.   BLOOD

Pre-clinical evaluation of AZD-2014, a novel mTORC1/2 dual inhibitor, against renal cell carcinoma

(2015) Bing Zheng et al.   CANCER LETTERS

First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014

(2015) B. Basu et al.   CLINICAL CANCER RESEARCH

Sirolimus and everolimus in kidney transplantation

(2015) Dirk Jan A.R. Moes et al.   DRUG DISCOVERY TODAY

The Interleukin-2-mTORc1 Kinase Axis Defines the Signaling, Differentiation, and Metabolism of T Helper 1 and Follicular B Helper T Cells

(2015) John P. Ray et al.   IMMUNITY

mTORC1 and mTORC2 selectively regulate CD8+ T cell differentiation

(2015) Kristen N. Pollizzi et al.   JOURNAL OF CLINICAL INVESTIGATION

De novo sirolimus with low-dose tacrolimus versus full-dose tacrolimus with mycophenolate mofetil after heart transplantation—8-year results

(2015) Sonja Guethoff et al.   JOURNAL OF HEART AND LUNG TRANSPLANTATION

mTOR Inhibition Per Se Induces Nuclear Localization of FOXP3 and Conversion of Invariant NKT (iNKT) Cells into Immunosuppressive Regulatory iNKT Cells

(2015) Charlotte M. Huijts et al.   JOURNAL OF IMMUNOLOGY

mTORC2 Deficiency in Myeloid Dendritic Cells Enhances Their Allogeneic Th1 and Th17 Stimulatory Ability after TLR4 Ligation In Vitro and In Vivo

(2015) Dàlia Raïch-Regué et al.   JOURNAL OF IMMUNOLOGY

SLC38A9 is a component of the lysosomal amino acid sensing machinery that controls mTORC1

(2015) Manuele Rebsamen et al.   NATURE

Treg cells require the phosphatase PTEN to restrain TH1 and TFH cell responses

(2015) Sharad Shrestha et al.   NATURE IMMUNOLOGY

The Ups and Downs of TORKinibs in Transplantation

(2015) Daniel Fantus et al.   TRANSPLANTATION

Safety and Efficacy of the Early Introduction of Everolimus With Reduced-Exposure Cyclosporine A in De Novo Kidney Recipients

(2015) Chang-Kwon Oh et al.   TRANSPLANTATION

Risk of Metabolic Complications in Kidney Transplantation After Conversion to mTOR Inhibitor: A Systematic Review and Meta-Analysis

(2014) N. Murakami et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Sirolimus Use and Cancer Incidence Among US Kidney Transplant Recipients

(2014) E. L. Yanik et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Five-Year Outcomes in Kidney Transplant Patients Converted From Cyclosporine to Everolimus: The Randomized ZEUS Study

(2014) K. Budde et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Adenosine Triphosphate-Competitive mTOR Inhibitors: A New Class of Immunosuppressive Agents That Inhibit Allograft Rejection

(2014) B. R. Rosborough et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Biomarkers of calcineurin inhibitor nephrotoxicity in transplantation

(2014) Mangalee Fernando et al.   Biomarkers in Medicine

Conversion to everolimus dramatically improves the prognosis ofde novomalignancies after liver transplantation for alcoholic liver disease

(2014) Elsa Thimonier et al.   CLINICAL TRANSPLANTATION

The effect of mammalian target of rapamycin inhibition on T helper type 17 and regulatory T cell differentiationin vitroandin vivoin kidney transplant recipients

(2014) Kyoung Woon Kim et al.   IMMUNOLOGY

mTOR signaling, Tregs and immune modulation

(2014) Nicole M Chapman et al.   Immunotherapy

Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib

(2014) Andrew X. Zhu et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation

(2014) Michael J.G. Somers et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Rapamycin antagonizes TNF induction of VCAM-1 on endothelial cells by inhibiting mTORC2

(2014) Chen Wang et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Cutting Edge: Discrete Functions of mTOR Signaling in Invariant NKT Cell Development and NKT17 Fate Decision

(2014) Jun Wei et al.   JOURNAL OF IMMUNOLOGY

Mammalian Target of Rapamycin Complex 2 Modulates   TCR Processing and Surface Expression during Thymocyte Development

(2014) P.-C. Chou et al.   JOURNAL OF IMMUNOLOGY

Mechanistic Target of Rapamycin Inhibition Extends Cellular Lifespan in Dendritic Cells by Preserving Mitochondrial Function

(2014) Eyal Amiel et al.   JOURNAL OF IMMUNOLOGY

Mammalian Target of Rapamycin Complex 1 Orchestrates Invariant NKT Cell Differentiation and Effector Function

(2014) Lianjun Zhang et al.   JOURNAL OF IMMUNOLOGY

The AGC kinase SGK1 regulates TH1 and TH2 differentiation downstream of the mTORC2 complex

(2014) Emily B Heikamp et al.   NATURE IMMUNOLOGY

Inhibition of the mTORC Pathway in the Antiphospholipid Syndrome

(2014) Guillaume Canaud et al.   NEW ENGLAND JOURNAL OF MEDICINE

mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition

(2014) Jose J. Limon et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Renal function three years after early conversion from a calcineurin inhibitor to everolimus: results from a randomized trial in kidney transplantation

(2014) Lars Mjörnstedt et al.   TRANSPLANT INTERNATIONAL

Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review

(2014) Evangelos Cholongitas et al.   TRANSPLANT INTERNATIONAL

Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data

(2014) G. A. Knoll et al.   BMJ-British Medical Journal

Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014

(2013) Hai-zhong Huo et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014

(2013) Kurt G. Pike et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

The late endosomal adaptor molecule p14 (LAMTOR2) represents a novel regulator of Langerhans cell homeostasis

(2013) F. Sparber et al.   BLOOD

Requirement for Rictor in homeostasis and function of mature B lymphoid cells

(2013) K. Lee et al.   BLOOD

Rapamycin has suppressive and stimulatory effects on human plasmacytoid dendritic cell functions

(2013) P. P. C. Boor et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

The pros and the cons of mTOR inhibitors in kidney transplantation

(2013) Claudio Ponticelli   Expert Review of Clinical Immunology

Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells

(2013) Chen Wang et al.   JOURNAL OF CLINICAL INVESTIGATION

Decreased incidence of cytomegalovirus infection with sirolimus in a post hoc randomized, multicenter study in lung transplantation

(2013) Bijan Ghassemieh et al.   JOURNAL OF HEART AND LUNG TRANSPLANTATION

mTOR kinase structure, mechanism and regulation

(2013) Haijuan Yang et al.   NATURE

mTORC1 couples immune signals and metabolic programming to establish Treg-cell function

(2013) Hu Zeng et al.   NATURE

Natural and inducible TH17 cells are regulated differently by Akt and mTOR pathways

(2013) Jiyeon S Kim et al.   NATURE IMMUNOLOGY

The kinase mTOR modulates the antibody response to provide cross-protective immunity to lethal infection with influenza virus

(2013) Rachael Keating et al.   NATURE IMMUNOLOGY

Amino acid signalling upstream of mTOR

(2013) Jenna L. Jewell et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Racial Comparisons of Everolimus Pharmacokinetics and Pharmacodynamics in Adult Kidney Transplant Recipients

(2013) David J. Taber et al.   THERAPEUTIC DRUG MONITORING

Abrogation of Chronic Rejection in Rat Model System Involves Modulation of the mTORC1 and mTORC2 Pathways

(2013) Li Zhang et al.   TRANSPLANTATION

Regulatory T Cells Exhibit Decreased Proliferation but Enhanced Suppression After Pulsing With Sirolimus

(2012) K. Singh et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Donor-Specific HLA Antibodies in a Cohort Comparing Everolimus With Cyclosporine After Kidney Transplantation

(2012) L. Liefeldt et al.   AMERICAN JOURNAL OF TRANSPLANTATION

CMV Late Phase-Induced mTOR Activation Is Essential for Efficient Virus Replication in Polarized Human Macrophages

(2012) M. Poglitsch et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Regulation of Immune Responses by mTOR

(2012) Jonathan D. Powell et al.   Annual Review of Immunology

Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma

(2012) A Naing et al.   BRITISH JOURNAL OF CANCER

mTOR Signaling in Growth Control and Disease

(2012) Mathieu Laplante et al.   CELL

Population Pharmacokinetics and Pharmacogenetics of Everolimus in Renal Transplant Patients

(2012) Dirk Jan A.R. Moes et al.   CLINICAL PHARMACOKINETICS

An evaluation of sirolimus in renal transplantation

(2012) Fabian Halleck et al.   Expert Opinion on Drug Metabolism & Toxicology

Inhibition of Mechanistic Target of Rapamycin Promotes Dendritic Cell Activation and Enhances Therapeutic Autologous Vaccination in Mice

(2012) E. Amiel et al.   JOURNAL OF IMMUNOLOGY

Ovarian Toxicity from Sirolimus

(2012) Matthias Braun et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sirolimus and Secondary Skin-Cancer Prevention in Kidney Transplantation

(2012) Sylvie Euvrard et al.   NEW ENGLAND JOURNAL OF MEDICINE

Flt3L Combined with Rapamycin Promotes Cardiac Allograft Tolerance by Inducing Regulatory Dendritic Cells and Allograft Autophagy in Mice

(2012) Ali Xiong et al.   PLoS One

Everolimus is associated with a reduced incidence of cytomegalovirus infection followingde novocardiac transplantation

(2012) J. Kobashigawa et al.   Transplant Infectious Disease

Wound Healing Complications and the Use of Mammalian Target of Rapamycin Inhibitors in Kidney Transplantation

(2012) Björn Nashan et al.   TRANSPLANTATION

Review of Cytomegalovirus Infection Findings With Mammalian Target of Rapamycin Inhibitor-Based Immunosuppressive Therapy in De Novo Renal Transplant Recipients

(2012) Björn Nashan et al.   TRANSPLANTATION

Protor-1 is required for efficient mTORC2-mediated activation of SGK1 in the kidney

(2011) Laura R. Pearce et al.   BIOCHEMICAL JOURNAL

Direct activation of mTOR in B lymphocytes confers impairment in B-cell maturation andloss of marginal zone B cells

(2011) Sandrine Benhamron et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

HIF1α–dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Tregcells

(2011) Lewis Z. Shi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Rac1 Regulates the Activity of mTORC1 and mTORC2 and Controls Cellular Size

(2011) Abdelhafid Saci et al.   MOLECULAR CELL

The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2

(2011) Greg M Delgoffe et al.   NATURE IMMUNOLOGY

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Multicenter Phase 2 Trial of Sirolimus for Tuberous Sclerosis: Kidney Angiomyolipomas and Other Tumors Regress and VEGF- D Levels Decrease

(2011) Sandra L. Dabora et al.   PLoS One

Costimulatory blockade with mTor inhibition abrogates effector T-cell responses allowing regulatory T-cell survival in renal transplantation

(2011) Oriol Bestard et al.   TRANSPLANT INTERNATIONAL

Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials

(2011) Liset H. M. Pengel et al.   TRANSPLANT INTERNATIONAL

Noninfectious Pneumonitis after Everolimus Therapy for Advanced Renal Cell Carcinoma

(2010) Dorothy A. White et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Comparison of Sirolimus with Azathioprine in a Tacrolimus-based Immunosuppressive Regimen in Lung Transplantation

(2010) Sangeeta Bhorade et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

mTOR and GSK-3 shape the CD4+ T-cell stimulatory and differentiation capacity of myeloid DCs after exposure to LPS

(2010) H. R. Turnquist et al.   BLOOD

Myeloid-derived suppressor cells: Natural regulators for transplant tolerance

(2010) Peter Boros et al.   HUMAN IMMUNOLOGY

Mammalian Target of Rapamycin Controls Dendritic Cell Development Downstream of Flt3 Ligand Signaling

(2010) Taheri Sathaliyawala et al.   IMMUNITY

A Flt3L Encounter: mTOR Signaling in Dendritic Cells

(2010) Li Wu   IMMUNITY

Instructive cytokine signals in dendritic cell lineage commitment

(2010) Michael A. Schmid et al.   IMMUNOLOGICAL REVIEWS

Adoptive transfer of CD4+CD25+ regulatory cells combined with low-dose sirolimus and anti-thymocyte globulin delays acute rejection of renal allografts in Cynomolgus monkeys

(2010) Anlun Ma et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Monocytic suppressive cells mediate cardiovascular transplantation tolerance in mice

(2010) Mercedes Rodriguez Garcia et al.   JOURNAL OF CLINICAL INVESTIGATION

Cutting Edge: Rapamycin Augments Pathogen-Specific but Not Graft-Reactive CD8+ T Cell Responses

(2010) I. R. Ferrer et al.   JOURNAL OF IMMUNOLOGY

A Versatile Role of Mammalian Target of Rapamycin in Human Dendritic Cell Function and Differentiation

(2010) M. Haidinger et al.   JOURNAL OF IMMUNOLOGY

Rapamycin-Resistant mTORC1 Kinase Activity Is Required for Herpesvirus Replication

(2010) N. J. Moorman et al.   JOURNAL OF VIROLOGY

Rag proteins regulate amino-acid-induced mTORC1 signalling

(2009) Yasemin Sancak et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma

(2009) Christian Toso et al.   HEPATOLOGY

The mTOR Kinase Differentially Regulates Effector and Regulatory T Cell Lineage Commitment

(2009) Greg M. Delgoffe et al.   IMMUNITY

mTOR regulates memory CD8 T-cell differentiation

(2009) Koichi Araki et al.   NATURE

The Role of mTOR Inhibitors in the Management of Posttransplant Malignancy

(2009) Anthony P. Monaco   TRANSPLANTATION

Mammalian Target of Rapamycin Inhibitor Dyslipidemia in Kidney Transplant Recipients

(2008) B. L. Kasiske et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma

(2008) Augusto Villanueva et al.   GASTROENTEROLOGY

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

(2008) Robert J Motzer et al.   LANCET

Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma

(2008) Michael A. Zimmerman et al.   LIVER TRANSPLANTATION

The receptor tyrosine kinase Flt3 is required for dendritic cell development in peripheral lymphoid tissues

(2008) Claudia Waskow et al.   NATURE IMMUNOLOGY